TSK-031037

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameTSK-031037
Drug Alias NameTreg-depleting non-IL-2-blocking anti-CD25 antibody (Roche)aCD25-m2anon-IL-2 blocking anti-CD25 depleting antibody (Tusk Therapeutics)Fc-optimized Treg-depleting anti-CD25 antibody (Cancer Research UK/UCL/Tusk Therapeutics)aCD25NIB mIgG2a +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionImmunostimulantsInterleukin-2 receptor alpha chain modulatorsRegulatory T-lymphocytes inhibitors
TargetsInterleukin-2 receptor alpha chain
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of London
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRoche Holding LtdCancer Research UKTusk Therapeutics Ltd +[4] 
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A